Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-10-24

FDA Approved: DOVATO — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

The FDA approved a supplemental application for Dovato (dolutegravir and lamivudine) by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dovato (dolutegravir/lamivudine)

Snippet

SUPPL AP for DOVATO (DOLUTEGRAVIR SODIUM AND LAMIVUDINE)